Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the KSA.
Campus
  • Payor
Campus
  • Payor

Differential diagnostics for ASMD in patients suspected to have GD

Objective

  • To demonstrate benefits of differential diagnosis within primary diagnostic testing.
  • To improve detection rate of potential ASMD, avoid diagnostic delays.

A multicenter, prospective study

DBS testing

  • GBA enzyme activity
  • ASM enzyme activity

Positive Cases

  • Genetic confirmatory testing

Results

Genetic confirmatory testing done for 5933 cases

SMPD1 gene sequencing for 1171 cases GBA gene sequencing for 4762 cases

 

ASMD:GD varies by region

Overall, 1 out of 4 patients with suspected GD suffered from ASMD.

 

Overall, 51% of ASMD cases were newborns.

5933 symptomatic cases showed decreased enzyme activities

227 distinct SMPD1 sequence variants identified

10 more frequent variants

Most of the cases with ASMD from the Middle East were newborns and with GD were adults.

 Higher number of confirmed ASMD patients in Pakistan, Iraq, Turkey, and Iran

 

Egypt had the highest number of GD cases followed by Turkey, while Iraq had the highest number of ASMD cases.

Conclusion

ASM: Acid sphingomyelinase; ASMD: Acid sphingomyelinase deficiency; DBS: Dried blood spots; GBA: Acid- -glucocerebrosidase; GD: Gaucher disease; KSA: Kingdom of Saudi Arabia; SMPD1: Sphingomyelin phosphodiesterase 1; UAE: United Arab Emirates.

  1. Oliva P, Schwarz M, Mechtler TP, et al. Importance to include differential diagnostics for acid sphingomyelinase deficiency (ASMD) in patients suspected to have to Gaucher disease. Mol Genet Metab. 2023;139(1):107563.
Related articles
MAT-BH-2400114-V1-February 2024